Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia (FFA)
Frontal Fibrosing Alopecia
About this trial
This is an interventional treatment trial for Frontal Fibrosing Alopecia focused on measuring cicatricial alopecia, treatment, placebo, double-blind
Eligibility Criteria
Inclusion Criteria:
- Patients with the diagnosis of Frontal Fibrosing Alopecia
Exclusion Criteria:
- Pregnancy
- Patient unable to accomplishing all fases of treatment
Sites / Locations
- Universitat Internacional Catalunya
Arms of the Study
Arm 1
Experimental
Corticosteroid/Saline
Corticosteroid/Saline Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia. In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo). The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions). This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6).